{
  "story_id": "81355a6c2d5c9cf87e9c503a51de215d",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-21T17:00:00.000Z",
  "content_hash": "1a233d260d1e561725353a4ebf1491b627be508aa9f2b8ccc869e4e33045811b",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Phase III Trial Shows Oral Deucrictibant Effectively Reduces HAE Attacks",
    "dek": "Novel oral drug deucrictibant demonstrated 83% lower HAE attack rates in phase III trial.",
    "prose": "In the CHAPTER-3 trial, extended-release deucrictibant reduced hereditary angioedema attack rate by 83% relative to placebo, to 0.35 events per month versus 2.06 for placebo. [^1]\n\nMarc A. Riedl, MD of University of California San Diego presented phase III CHAPTER-3 trial results for deucrictibant at the November 20 2026 American College of Allergy, Asthma & Immunology annual meeting. [^2] ModuleMD showcased its new AI-integrated allergy EHR platform at the 2026 ACAAI Annual Scientific Meeting held in Phoenix, Arizona. [^3] ModuleMD states its WISE Touch AI embeds AI capabilities directly into standard clinical and administrative EHR workflows. [^4]\n\n45% of deucrictibant treated trial patients remained attack-free over 24 weeks, compared to 3% of placebo group patients. [^5] Marc A. Riedl stated deucrictibant efficacy is comparable to existing subcutaneous injectable HAE prophylactic treatments. [^6] ModuleMD's JOSH AI tool converts natural clinical conversations into structured patient notes, supporting over 75 languages. [^7]\n\nModuleMD's SkinSight technology uses image AI to automatically measure and document allergy skin test wheal and flare reactions. [^8]",
    "cited": "[{\"statement\":\"In the CHAPTER-3 trial, extended-release deucrictibant reduced hereditary angioedema attack rate by 83% relative to placebo, to 0.35 events per month versus 2.06 for placebo.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T18:08:22.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"],\"url\":\"https://www.medpagetoday.com/meetingcoverage/acaai/123983\"},{\"statement\":\"Marc A. Riedl, MD of University of California San Diego presented phase III CHAPTER-3 trial results for deucrictibant at the November 20 2026 American College of Allergy, Asthma & Immunology annual meeting.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T18:08:22.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"],\"url\":\"https://www.medpagetoday.com/meetingcoverage/acaai/123983\"},{\"statement\":\"ModuleMD showcased its new AI-integrated allergy EHR platform at the 2026 ACAAI Annual Scientific Meeting held in Phoenix, Arizona.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T17:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"],\"url\":\"https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html\"},{\"statement\":\"ModuleMD states its WISE Touch AI embeds AI capabilities directly into standard clinical and administrative EHR workflows.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T17:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"],\"url\":\"https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html\"},{\"statement\":\"45% of deucrictibant treated trial patients remained attack-free over 24 weeks, compared to 3% of placebo group patients.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T18:08:22.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"],\"url\":\"https://www.medpagetoday.com/meetingcoverage/acaai/123983\"},{\"statement\":\"Marc A. Riedl stated deucrictibant efficacy is comparable to existing subcutaneous injectable HAE prophylactic treatments.\",\"source\":\"MedpageToday\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-20T18:08:22.000Z\",\"publisher_count\":1,\"sources\":[\"MedpageToday\"],\"url\":\"https://www.medpagetoday.com/meetingcoverage/acaai/123983\"},{\"statement\":\"ModuleMD's JOSH AI tool converts natural clinical conversations into structured patient notes, supporting over 75 languages.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T17:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"],\"url\":\"https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html\"},{\"statement\":\"ModuleMD's SkinSight technology uses image AI to automatically measure and document allergy skin test wheal and flare reactions.\",\"source\":\"Cision PR Newswire\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-21T17:00:00.000Z\",\"publisher_count\":1,\"sources\":[\"Cision PR Newswire\"],\"url\":\"https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "ce2e4e67ced1c8ecfd9556316f1748409c3911967eb1ac58be1fe77dd965c0a9",
    "cursor_from": "ingest:raw_newsroomfloor.stories:ce2e4e67ced1c8ec",
    "cursor_to": "ingest:raw_newsroomfloor.stories:ce2e4e67ced1c8ec",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "Mq3YbgrLaIrJ0ZTJp0ta2y9JqoWHO8cZ_cRMEj72JuvH8CxU2U_dzO3BNmK6t-K_3quL_XvC0yVM2aIkrnwWBQ",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "30590f9615b2a72946eee82de7e2e6c0",
      "thread_id": "1cf28315e2c019216fe43110dd2c4b1a",
      "thread_label": "American College of Allergy, Asthma & Immunology",
      "novelty": "UPDATE",
      "content_hash": "f47cc9d0d7411b05008420d00ac7f71b4a21322ec8930b88f93acb49efe3b6fb",
      "compose": 3,
      "last_published_at": "2026-11-21T17:00:00.000Z",
      "read_receipt": {
        "slice_hash": "56ea698fc80a14791cb56febff4c8a9a906b39934f3986c012794df63f3d308d",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMjFUMTQ6Mzk6NTcuMDAwWiIsImlkIjoiYjdiMDAyYTI0MWI3MTFlZDliOTQyY2MxYzQ5MmZlODciLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMjFUMTc6NDI6MjcuMDAwMDAwWiIsImlkIjoiMGIxNWVhYjFjZTM5YzAzY2QzODY3NTkzN2UzZDllNGIiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 44,
        "window_days": 3,
        "bytes_scanned": 2447567,
        "credits": 3.52,
        "price_per_100_rows": 8,
        "sig": "YsaYytRpsngf2lTFkinAsKdFXOxki1B9ckidJ9VBu4TKM2LYrMeM_4sKDaHv38cVvP1sb0Rapwa-Flqvxei2Bw",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-21T18:26:13.691Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "In the CHAPTER-3 trial, extended-release deucrictibant reduced hereditary angioedema attack rate by 83% relative to placebo, to 0.35 events per month versus 2.06 for placebo.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/meetingcoverage/acaai/123983",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "Marc A. Riedl, MD of University of California San Diego presented phase III CHAPTER-3 trial results for deucrictibant at the November 20 2026 American College of Allergy, Asthma & Immunology annual meeting.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/meetingcoverage/acaai/123983",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "ModuleMD showcased its new AI-integrated allergy EHR platform at the 2026 ACAAI Annual Scientific Meeting held in Phoenix, Arizona.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "ModuleMD states its WISE Touch AI embeds AI capabilities directly into standard clinical and administrative EHR workflows.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "45% of deucrictibant treated trial patients remained attack-free over 24 weeks, compared to 3% of placebo group patients.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/meetingcoverage/acaai/123983",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Marc A. Riedl stated deucrictibant efficacy is comparable to existing subcutaneous injectable HAE prophylactic treatments.",
      "source": "MedpageToday",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.medpagetoday.com/meetingcoverage/acaai/123983",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "ModuleMD's JOSH AI tool converts natural clinical conversations into structured patient notes, supporting over 75 languages.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "ModuleMD's SkinSight technology uses image AI to automatically measure and document allergy skin test wheal and flare reactions.",
      "source": "Cision PR Newswire",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.prnewswire.com/news-releases/modulemd-continues-to-strengthen-its-position-in-allergy-ehr-innovation-with-a-new-generation-of-ai-powered-technology-302945885.html",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}